• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    PDS Biotechnology Corporation - Common Stock (NQ:PDSB)

    0.9360 -0.0040 (-0.43%)
    Streaming Delayed Price Updated: 3:56 PM EST, Nov 3, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about PDS Biotechnology Corporation - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval
    The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial. 
    Via Stocktwits
    Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026
    Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids. 
    Via Stocktwits
    PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Narrower Q2 2025 Loss, Stock Rises on Clinical Progress
    PDS Biotechnology (PDSB) reported Q2 2025 EPS of -$0.21, beating estimates. Stock rose 8.13% pre-market as clinical progress, including ASCO presentations, boosts investor optimism. No revenue yet. 
    Via Chartmill
    PDSB Loss Improves as Costs Drop
    Via The Motley Fool
    12 Health Care Stocks Moving In Wednesday's After-Market Session
     
    Via Benzinga
    Insights Ahead: PDS Biotechnology's Quarterly Earnings
     
    Via Benzinga
    A Look at PDS Biotechnology's Upcoming Earnings Report
     
    Via Benzinga
    Earnings Scheduled For August 13, 2025
     
    Via Benzinga
    Insights into PDS Biotechnology's Upcoming Earnings
     
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
     
    Via Benzinga
    PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish
    The company said the reduced losses were primarily due to decreased operating expenses. 
    Via Stocktwits
    Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    Uncovering Potential: PDS Biotechnology's Earnings Preview
     
    Via Benzinga
    Earnings Preview For PDS Biotechnology
     
    Via Benzinga
    Analyst Expectations for PDS Biotechnology's Future
     
    Via Benzinga
    Earnings Scheduled For May 14, 2025
     
    Via Benzinga
    PDS Biotechnology: Q3 Earnings Insights
     
    Via Benzinga
    Earnings Scheduled For March 27, 2025
     
    Via Benzinga
    Life Sciences Investor Forum Agenda Announced for March 13th
    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
    From Virtual Investor Conferences
    Via GlobeNewswire
    A Preview Of PDS Biotechnology's Earnings
     
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
     
    Via Benzinga
    PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q2 2024
    PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024
    PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's Intraday Session
     
    Via Benzinga
    PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023
    PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    The Latest Analyst Ratings for PDS Biotechnology
     
    Via Benzinga
    Earnings Scheduled For November 14, 2024
     
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
     
    Via Benzinga
    Earnings Scheduled For March 27, 2024
    Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. 
    Via Benzinga
    The 3 Most Undervalued Biotech Stocks to Buy in March 2024
    These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.